XLRN News and Press, Acceleron Pharma Inc. From 08/06/20

Acceleron Pharma (NASDAQ: XLRN ) : Q2 GAAP EPS of -$0.34 beats by $0.20 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Acceleron recognized approximately $11.1 million in royalty revenue for Q2 2020 from approximately $55.0 million in net U.S. sales of REBLOZYL ® (luspatercept-aamt) and a $25.0 million regulatory-based milestone from Bristol Myers Squibb - - REBLOZYL, the first and only erythro...

- Acceleron expects to report approximately $11.1 million in royalty revenue for Q2 2020 from approximately $55.0 million in net U.S. sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb - - Acceleron will report its full second quarter 2020 financial and o...

Acceleron Pharma (XLRN), Tandem Diabetes Care (TNDM), and CRISPR Therapeutics (CRSP) are three overvalued healthcare stocks investor should avoid for now. The coronavirus pandemic has wreaked havoc on many industries, but healthcare has not been one of them. Pharmacies have seen increased s...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, August 6, 2020 at 5:00 p.m. EDT to discuss its second quarter 2020 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investor...

Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has issued an aggregate of 5,594,593 shares of common stock at a pric...

Acceleron Pharma (NASDAQ: XLRN ) has priced its public offering of 4,864,864 common shares at $92.50/share, for gross proceeds of $450M. More news on: Acceleron Pharma Inc., Healthcare stocks news, , Read more ...

Acceleron Reports Positive Top-Line Results for PULSAR Trial Acceleron Pharma, Inc. (XLRN) announced top-line results from its Phase 2 trial testing sotatercept in patients with pulmonary arterial hypertension. The trial involved 106 patients who were randomized to be administered placebo,...

Reblozyl regulates late-stage red blood cell (RBC) maturation to potentially reduce or eliminate the need for regular RBC transfusions Reblozyl is the first and only erythroid maturation agent to be approved in the European Union, representing a new class of therapy Bristol M...

Acceleron Pharma ( XLRN -5.5% ) announces positive results from a Phase 2 clinical trial, PULSAR , evaluating sotatercept in pulmonary arterial hypertension (PAH) patients. The data were presented virtually at the American Thoracic Society Conference. More news on: Acceleron Pharma In...